言語を選択

Apo-A1

Apo-A1 詳細

英語名	Apolipoprotein A-I	市販薬剤の数	0
治験薬の数	3	ターゲットの別称	Epididymis Secretory Sperm Binding Protein，Apolipoprotein A-I(1-242)，APOA1，ProapoA-I，Apo-AI，Apolipoprotein A1，Apo(A)，ApoA-I，Apolipoprotein A-I，HPALP2
研究＆開発段階	Phase 2 Clinical

英語名	Apolipoprotein A-I
ターゲットの別称	Epididymis Secretory Sperm Binding Protein，Apolipoprotein A-I(1-242)，APOA1，ProapoA-I，Apo-AI，Apolipoprotein A1，Apo(A)，ApoA-I，Apolipoprotein A-I，HPALP2
市販薬剤の数	0
治験薬の数	3
研究＆開発段階	Phase 2 Clinical

Apo-A1 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
His Tag (1)
マーカー
Unconjugated (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
AP1-H5225	Human	HEK293	Human Apo-A1 Protein, His Tag

総数量1

Apo-A1バックグランド

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1分子の別称

Apolipoprotein A-I,APOA1,MGC117399

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Zerlasiran	SLN-360	Phase 2 Clinical	Silence Therapeutics Plc	Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders	詳細
Fx-5A	Fx-5A	Phase 1 Clinical	Kinemed Inc	Cardiovascular Diseases	詳細
Recombinant NV-A01 adenovirus		Phase 1 Clinical	Nanjing Nuowei Biotechnology Co Ltd	Glioblastoma; Solid tumours	詳細